HRP20150290T1 - Metoda lijeäśenja karcinoma prostate s gnrh antagonistom degareliksom - Google Patents
Metoda lijeäśenja karcinoma prostate s gnrh antagonistom degareliksom Download PDFInfo
- Publication number
- HRP20150290T1 HRP20150290T1 HRP20150290AT HRP20150290T HRP20150290T1 HR P20150290 T1 HRP20150290 T1 HR P20150290T1 HR P20150290A T HRP20150290A T HR P20150290AT HR P20150290 T HRP20150290 T HR P20150290T HR P20150290 T1 HRP20150290 T1 HR P20150290T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- use according
- subject
- treatment
- degarelix
- Prior art date
Links
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 title claims 6
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 title claims 6
- 229960002272 degarelix Drugs 0.000 title claims 6
- 206010060862 Prostate cancer Diseases 0.000 title claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims 3
- 239000002474 gonadorelin antagonist Substances 0.000 title 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims 3
- 102100032752 C-reactive protein Human genes 0.000 claims 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 206010003671 Atrioventricular Block Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000019504 cigarettes Nutrition 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (14)
1. Sastav koji sadrži degareliks za upotrebu u liječenju karcinoma prostate kod subjekta identificiranog kao rizičnog za kardiovaskularnu bolest.
2. Sastav koji sadrži degareliks za upotrebu u liječenju karcinoma prostate u subjekta, gdje je kod subjekta identificirano da ima povećanu vjerojatnost razvoja kardiovaskularne bolesti ili poremećaj.
3. Sastav za upotrebu prema patentnom zahtjevu 1 ili 2 za primjenu u inicijalnoj dozi degareliks od 160 do 320 mg;
i održavajućoj dozi od 60 do 160 mg, jednom svakih 20 do 36 dana nakon toga.
4. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu za primjenu u inicijalnoj dozi degareliksa od oko 240 mg; i održavajućoj dozi od oko 80 mg degareliksa jednom svakih prosječno 28 dana liječenja.
5. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu za liječenje subjekta s razinom kolesterola većom ili jednakom 4 mmol/L.
6. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu za liječenje subjekta koji posjeduje indikator povećanog i/ili velikog rizika kardiovaskularnih bolesti.
7. Sastav za upotrebu prema patentnom zahtjevu 6, naznačen time da je indikator povećanog rizika kardiovaskularnih bolesti jedan ili više od povećanog krvnog tlaka, visoki kolesterol lipoproteina male gustoće (LDL), niski kolesterol lipoproteina visoke gustoće, visoki serum glukoze i navika pušenja.
8. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu za liječenje subjekta s krvnim tlakom većim ili jednakim 130 prema 85 mm Hg.
9. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu za liječenje subjekta koji dnevno puši cigarete.
10. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu za liječenje subjekta s kolesterolom lipoproteina male gustoće većem ili jednakom od oko 160 mg/dL i/ili razinom kolesterola lipoproteina visoke gustoće manjom od 35 mg/dL.
11. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu za liječenje subjekta s razinom glukoze nakon posta većom od oko 120 mg/dL.
12. Sastav za upotrebu prema patentnom zahtjevu 6, naznačen time da je indikator visokog rizika za kardiovaskularne bolesti jedan ili više od visoki serum C-reaktivnog proteina (CRP), visoki serum homocisteina, visoki serum fibrinogena, i visoki serum lipoproteina (a) (Lp(a)).
13. Sastav za upotrebu prema patentnom zahtjevu 12, naznačen time da je za liječenje subjekta s jednim ili više od: razina C-reaktivnog proteina veća od 3 mg/dL; razina seruma homocisteina veća od 30 mmol/L; razina seruma fibrinogena veća od 7.0 g/L; i razina seruma Lp(a) veća od 30 mg/dL.
14. Sastav za upotrebu prema bilo kojem prethodnom patentnom zahtjevu, naznačen time da kardiovaskularna bolest ili poremećaj je šum, atrioventrikularna blokada ili miokardialna ishemija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2774108P | 2008-02-11 | 2008-02-11 | |
| EP08250703 | 2008-02-29 | ||
| EP12165896.7A EP2505204B1 (en) | 2008-02-11 | 2009-02-10 | Method of treating prostate cancer with the GnRH antagonist degarelix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150290T1 true HRP20150290T1 (hr) | 2015-04-10 |
Family
ID=39718285
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140665AT HRP20140665T1 (hr) | 2008-02-11 | 2014-07-14 | Lijeäśenje metastatskog stadija raka prostate pomoä†u degareliksa |
| HRP20150290AT HRP20150290T1 (hr) | 2008-02-11 | 2015-03-16 | Metoda lijeäśenja karcinoma prostate s gnrh antagonistom degareliksom |
| HRP20150633TT HRP20150633T1 (hr) | 2008-02-11 | 2015-06-12 | Lijeäśenje karcinoma prostate u metastaznoj fazi s degareliksom |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140665AT HRP20140665T1 (hr) | 2008-02-11 | 2014-07-14 | Lijeäśenje metastatskog stadija raka prostate pomoä†u degareliksa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150633TT HRP20150633T1 (hr) | 2008-02-11 | 2015-06-12 | Lijeäśenje karcinoma prostate u metastaznoj fazi s degareliksom |
Country Status (25)
| Country | Link |
|---|---|
| US (15) | US8841081B2 (hr) |
| EP (7) | EP2249858A1 (hr) |
| JP (10) | JP5924866B2 (hr) |
| KR (7) | KR20220009504A (hr) |
| CN (4) | CN101939020B (hr) |
| AU (2) | AU2009213748B9 (hr) |
| BR (2) | BRPI0908129A2 (hr) |
| CA (3) | CA3235099A1 (hr) |
| CY (3) | CY1115561T1 (hr) |
| DK (3) | DK2650012T3 (hr) |
| EA (4) | EA017582B1 (hr) |
| ES (3) | ES2532709T3 (hr) |
| HK (4) | HK1145011A1 (hr) |
| HR (3) | HRP20140665T1 (hr) |
| IL (3) | IL207295A (hr) |
| JO (1) | JOP20090061B1 (hr) |
| MX (2) | MX2010008816A (hr) |
| NZ (4) | NZ587088A (hr) |
| PL (3) | PL2650012T3 (hr) |
| PT (3) | PT2650012E (hr) |
| RU (2) | RU2504393C2 (hr) |
| SI (3) | SI2650012T1 (hr) |
| TW (2) | TWI442932B (hr) |
| WO (2) | WO2009101533A1 (hr) |
| ZA (1) | ZA201005697B (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| JO3525B1 (ar) * | 2008-02-11 | 2020-07-05 | Ferring Int Center Sa | علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس |
| EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| FR2964323B1 (fr) * | 2010-09-08 | 2012-11-09 | Jean Pierre Raynaud | Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate |
| PL2632934T3 (pl) | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| BR112013023050A8 (pt) * | 2011-03-09 | 2018-09-25 | G Pestell Richard | antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal |
| CN102204889B (zh) * | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
| WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
| CA2873743C (en) | 2012-05-14 | 2022-12-06 | Prostagene, Llc | Using modulators of ccr5 for treating cancer |
| AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
| KR20220025231A (ko) | 2012-09-26 | 2022-03-03 | 아라곤 파마슈티컬스, 인코포레이티드 | 비전이성 거세 저항성 전립선암 치료용 항안드로겐 |
| JP6159870B2 (ja) | 2013-03-15 | 2017-07-05 | アッヴィ・インコーポレイテッド | 月経出血過多および子宮類線維腫の処置に使用するための組成物 |
| US20140358576A1 (en) * | 2013-05-15 | 2014-12-04 | Adverse Events, Inc. | System and method for surveillance and evaluation of safety risks associated with medical interventions |
| AU2015308987B2 (en) * | 2014-08-26 | 2021-02-18 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| JP6941565B2 (ja) * | 2015-05-12 | 2021-09-29 | ドレクセル ユニバーシティ | がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法 |
| US20200000872A1 (en) * | 2017-01-30 | 2020-01-02 | Antev Limited | A composition comprising at least one gnrh antagonist |
| KR20200070334A (ko) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| CN112261942A (zh) | 2018-04-19 | 2021-01-22 | 艾伯维公司 | 治疗重度月经出血的方法 |
| CA3107597A1 (en) * | 2018-08-01 | 2020-02-06 | Abbvie Inc. | Dosing regimens for elagolix |
| RU2731002C1 (ru) * | 2019-10-22 | 2020-08-26 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ лечения рака предстательной железы |
| CN116407494B (zh) * | 2023-03-02 | 2024-07-09 | 山东大学齐鲁医院 | 一种醋酸地加瑞克注射液及其制备方法、用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4072668A (en) | 1973-11-06 | 1978-02-07 | The Salk Institute For Biological Studies | LH-RH Analogs |
| EP0002749B2 (en) | 1977-12-26 | 1987-08-12 | IHARA CHEMICAL INDUSTRY Co., Ltd. | Process for producing aromatic monocarboxylic acid |
| US5296468A (en) | 1989-10-30 | 1994-03-22 | The Salk Institute For Biological Studies | GnRH analogs |
| DE593491T1 (de) | 1991-04-25 | 1994-11-17 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten. |
| EP0556034B2 (en) | 1992-02-12 | 2004-07-21 | Daikyo Gomu Seiko Ltd. | A medical instrument |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5825730A (en) | 1995-03-10 | 1998-10-20 | Kabushiki Kaisha Toshiba | Mastering machine having non-repetitive runout compensation |
| US6379669B1 (en) | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
| US5710246A (en) | 1996-03-19 | 1998-01-20 | Abbott Laboratories | Process for intermediates for the synthesis of LHRH antagonists |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| WO1999026964A1 (en) | 1997-11-20 | 1999-06-03 | Ortho-Mcneil Pharmaceutical, Inc. | LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| ES2389627T3 (es) | 1998-07-20 | 2012-10-29 | Virbac (Australia) Pty Ltd | Formulación para bioimplantes |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US20020103131A1 (en) | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| US7045605B2 (en) * | 2001-06-01 | 2006-05-16 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| GB0117057D0 (en) | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20060234918A1 (en) * | 2001-12-19 | 2006-10-19 | Voyager Pharmaceutical Corporation | Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors |
| US20070015713A1 (en) | 2005-07-14 | 2007-01-18 | Voyager Pharmaceutical Corporation | Methods for treating prostate cancer |
| SE0104463D0 (sv) | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister |
| CN1411803A (zh) | 2002-08-29 | 2003-04-23 | 四川大学 | 制备前体脂质体的方法及其装置 |
| CN100509053C (zh) | 2002-09-27 | 2009-07-08 | 赞塔里斯有限公司 | 持续释放的药物活性肽施用形式及其制备方法 |
| GB0223367D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Therapeutic treatment |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| WO2006069779A1 (en) | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Preparing of peptides with excellent solubility |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| WO2007130809A2 (en) | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
| EP1891964A1 (en) | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| IL182922A0 (en) | 2007-05-02 | 2007-09-20 | Medimop Medical Projects Ltd | Automatic liquid drug reconstitution apparatus |
| US8283331B2 (en) | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| KR20100120289A (ko) | 2008-01-15 | 2010-11-15 | 애보트 게엠베하 운트 콤파니 카게 | 분말상 단백질 조성물 및 이의 제조 방법 |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| WO2009102720A1 (en) * | 2008-02-11 | 2009-08-20 | Safety Syringes, Inc. | Reconstitution means for safety device |
| SG175744A1 (en) | 2009-04-24 | 2011-12-29 | Polypeptide Laboratories As | Method for the manufacture of degarelix |
| EP2424503B1 (en) | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
| TW201043221A (en) | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| WO2011066386A1 (en) | 2009-11-25 | 2011-06-03 | Novetide, Ltd. | Process for production of degarelix |
| ES2385240B1 (es) | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
| PL2632934T3 (pl) | 2010-10-27 | 2017-06-30 | Ferring B.V. | Sposób wytwarzania degareliksu i jego związków pośrednich |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| CN102204889B (zh) | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
| PL2731607T3 (pl) | 2011-07-15 | 2018-03-30 | Ferring B.V. | Sposób koordynacji czasu kolonoskopii, w którym podaje się kompozycję pikosiarczanową |
| AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
-
2009
- 2009-02-09 TW TW098104075A patent/TWI442932B/zh active
- 2009-02-09 JO JOP/2009/0061A patent/JOP20090061B1/ar active
- 2009-02-09 TW TW098104073A patent/TWI539959B/zh active
- 2009-02-10 PT PT131684045T patent/PT2650012E/pt unknown
- 2009-02-10 DK DK13168404.5T patent/DK2650012T3/da active
- 2009-02-10 PL PL13168404T patent/PL2650012T3/pl unknown
- 2009-02-10 EP EP09709538A patent/EP2249858A1/en not_active Ceased
- 2009-02-10 US US12/368,713 patent/US8841081B2/en active Active
- 2009-02-10 KR KR1020227000962A patent/KR20220009504A/ko not_active Application Discontinuation
- 2009-02-10 WO PCT/IB2009/000370 patent/WO2009101533A1/en active Application Filing
- 2009-02-10 SI SI200931181T patent/SI2650012T1/sl unknown
- 2009-02-10 NZ NZ587088A patent/NZ587088A/xx unknown
- 2009-02-10 BR BRPI0908129-1A patent/BRPI0908129A2/pt not_active Application Discontinuation
- 2009-02-10 RU RU2010133481/15A patent/RU2504393C2/ru active
- 2009-02-10 ES ES12165896.7T patent/ES2532709T3/es active Active
- 2009-02-10 CA CA3235099A patent/CA3235099A1/en active Pending
- 2009-02-10 MX MX2010008816A patent/MX2010008816A/es active IP Right Grant
- 2009-02-10 NZ NZ587057A patent/NZ587057A/xx unknown
- 2009-02-10 CN CN200980104713XA patent/CN101939020B/zh active Active
- 2009-02-10 SI SI200930942T patent/SI2249859T1/sl unknown
- 2009-02-10 PT PT97113906T patent/PT2249859E/pt unknown
- 2009-02-10 DK DK09711390.6T patent/DK2249859T3/da active
- 2009-02-10 CN CN201410247166.3A patent/CN103990107A/zh active Pending
- 2009-02-10 NZ NZ603932A patent/NZ603932A/en unknown
- 2009-02-10 MX MX2010008817A patent/MX2010008817A/es active IP Right Grant
- 2009-02-10 EA EA200901074A patent/EA017582B1/ru not_active IP Right Cessation
- 2009-02-10 NZ NZ603958A patent/NZ603958A/xx unknown
- 2009-02-10 PT PT12165896T patent/PT2505204E/pt unknown
- 2009-02-10 CN CN2009801127793A patent/CN101998861A/zh active Pending
- 2009-02-10 SI SI200931138T patent/SI2505204T1/sl unknown
- 2009-02-10 PL PL12165896T patent/PL2505204T3/pl unknown
- 2009-02-10 EP EP23174353.5A patent/EP4257197A3/en active Pending
- 2009-02-10 ES ES13168404.5T patent/ES2540235T3/es active Active
- 2009-02-10 EP EP18151844.0A patent/EP3360565A1/en active Pending
- 2009-02-10 US US12/368,935 patent/US20090203623A1/en not_active Abandoned
- 2009-02-10 AU AU2009213748A patent/AU2009213748B9/en active Active
- 2009-02-10 CN CN201710169651.7A patent/CN107412726A/zh active Pending
- 2009-02-10 KR KR1020237019555A patent/KR20230088848A/ko not_active Application Discontinuation
- 2009-02-10 CA CA2714444A patent/CA2714444A1/en active Pending
- 2009-02-10 EP EP13168404.5A patent/EP2650012B1/en not_active Revoked
- 2009-02-10 KR KR1020107020035A patent/KR101542480B1/ko active IP Right Grant
- 2009-02-10 EP EP09711390.6A patent/EP2249859B1/en not_active Revoked
- 2009-02-10 EP EP14170557.4A patent/EP2799085A1/en not_active Ceased
- 2009-02-10 BR BRPI0908127-5A patent/BRPI0908127A2/pt not_active Application Discontinuation
- 2009-02-10 EA EA201300741A patent/EA036695B1/ru not_active IP Right Cessation
- 2009-02-10 KR KR1020187030959A patent/KR20180118830A/ko not_active Application Discontinuation
- 2009-02-10 AU AU2009213751A patent/AU2009213751B2/en active Active
- 2009-02-10 CA CA2714445A patent/CA2714445C/en not_active Expired - Fee Related
- 2009-02-10 RU RU2010133480/15A patent/RU2504394C2/ru active
- 2009-02-10 JP JP2010545575A patent/JP5924866B2/ja active Active
- 2009-02-10 WO PCT/IB2009/000350 patent/WO2009101530A1/en active Application Filing
- 2009-02-10 JP JP2010545576A patent/JP5876652B2/ja active Active
- 2009-02-10 KR KR1020107020036A patent/KR20100123714A/ko active Application Filing
- 2009-02-10 KR KR1020147030003A patent/KR20140130757A/ko active Search and Examination
- 2009-02-10 PL PL09711390T patent/PL2249859T3/pl unknown
- 2009-02-10 EA EA201300742A patent/EA026521B1/ru not_active IP Right Cessation
- 2009-02-10 DK DK12165896T patent/DK2505204T3/da active
- 2009-02-10 KR KR1020157020657A patent/KR20150091543A/ko active Application Filing
- 2009-02-10 EP EP12165896.7A patent/EP2505204B1/en not_active Revoked
- 2009-02-10 ES ES09711390.6T patent/ES2479441T3/es active Active
- 2009-02-10 EA EA200901075A patent/EA020543B1/ru unknown
-
2010
- 2010-07-29 IL IL207295A patent/IL207295A/en active IP Right Grant
- 2010-08-04 IL IL207400A patent/IL207400A/en active IP Right Grant
- 2010-08-10 ZA ZA2010/05697A patent/ZA201005697B/en unknown
- 2010-12-09 HK HK10111506.2A patent/HK1145011A1/xx unknown
- 2010-12-09 HK HK14103602.8A patent/HK1190912A1/xx unknown
- 2010-12-09 HK HK13103556.5A patent/HK1176552A1/xx not_active IP Right Cessation
- 2010-12-09 HK HK14111736.0A patent/HK1198243A1/xx unknown
-
2012
- 2012-04-27 US US13/458,330 patent/US9415085B2/en active Active
- 2012-11-19 IL IL223124A patent/IL223124A0/en unknown
-
2013
- 2013-12-24 US US14/139,922 patent/US9579359B2/en active Active
-
2014
- 2014-03-14 JP JP2014051197A patent/JP6189234B2/ja active Active
- 2014-04-22 JP JP2014087895A patent/JP6254042B2/ja active Active
- 2014-07-14 HR HRP20140665AT patent/HRP20140665T1/hr unknown
- 2014-07-18 CY CY20141100542T patent/CY1115561T1/el unknown
- 2014-08-08 US US14/454,825 patent/US9877999B2/en active Active
-
2015
- 2015-02-13 CY CY20151100155T patent/CY1116341T1/el unknown
- 2015-03-16 HR HRP20150290AT patent/HRP20150290T1/hr unknown
- 2015-05-14 CY CY20151100434T patent/CY1116289T1/el unknown
- 2015-06-12 HR HRP20150633TT patent/HRP20150633T1/hr unknown
-
2016
- 2016-05-11 JP JP2016095555A patent/JP2016193910A/ja active Pending
- 2016-05-18 JP JP2016099437A patent/JP2016216455A/ja active Pending
- 2016-07-08 US US15/205,108 patent/US10695398B2/en active Active
-
2017
- 2017-01-13 US US15/405,552 patent/US10729739B2/en active Active
- 2017-09-27 JP JP2017185676A patent/JP6618967B2/ja active Active
- 2017-12-18 US US15/845,391 patent/US20190167755A1/en not_active Abandoned
-
2020
- 2020-04-17 US US16/851,179 patent/US10973870B2/en active Active
- 2020-05-21 US US16/880,608 patent/US11766468B2/en active Active
-
2021
- 2021-03-12 US US17/199,733 patent/US20220031801A1/en active Pending
-
2022
- 2022-03-31 US US17/710,889 patent/US20220218782A1/en not_active Abandoned
- 2022-03-31 US US17/710,899 patent/US11826397B2/en active Active
- 2022-03-31 US US17/710,905 patent/US20220218783A1/en not_active Abandoned
- 2022-05-31 US US17/829,134 patent/US20220323538A1/en not_active Abandoned
- 2022-07-07 JP JP2022109616A patent/JP7400029B2/ja active Active
- 2022-09-08 JP JP2022142833A patent/JP2022184898A/ja active Pending
-
2023
- 2023-12-06 JP JP2023206150A patent/JP2024028869A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150290T1 (hr) | Metoda lijeäśenja karcinoma prostate s gnrh antagonistom degareliksom | |
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| Sen et al. | Cystathionine β-synthase and cystathionine γ-lyase double gene transfer ameliorate homocysteine-mediated mesangial inflammation through hydrogen sulfide generation | |
| BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
| PH12015502136A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| MEP27308A (en) | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
| UA117570C2 (uk) | Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті | |
| MX2007000304A (es) | Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. | |
| MX355482B (es) | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. | |
| WO2014004993A3 (en) | Methods of reducing ldl-p | |
| EA200970251A1 (ru) | Антитела к миостатину | |
| WO2006122257A3 (en) | Nebulization of monoclonal antibodies for treating pulmonary diseases | |
| BR112013023724A2 (pt) | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| EA201390335A1 (ru) | Введение лоркасерина индивидуумам с почечной недостаточностью | |
| Chakkarwar | Fenofibrate attenuates nicotine-induced vascular endothelial dysfunction in the rat | |
| Chen et al. | Hypercysteinemia promotes atherosclerosis by reducing protein S-nitrosylation | |
| BR112022007252A2 (pt) | Método de tratamento de uma doença hepática e composição | |
| BR112020012668A8 (pt) | Composição para o tratamento de um paciente com doença respiratória associada a inflamações crônicas e método de produção e utilização da composição |